Leonard Post Net Worth

The estimated Net Worth of Leonard E Post is at least $163 Тысяча dollars as of 13 June 2024. Leonard Post owns over 2,222 units of uniQure N.V stock worth over $87,515 and over the last 4 years he sold QURE stock worth over $75,464. In addition, he makes $0 as Director at uniQure N.V.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Leonard Post QURE stock SEC Form 4 insiders trading

Leonard has made over 4 trades of the uniQure N.V stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,222 units of QURE stock worth $11,421 on 13 June 2024.

The largest trade he's ever made was selling 2,291 units of uniQure N.V stock on 13 June 2023 worth over $43,140. On average, Leonard trades about 570 units every 84 days since 2020. As of 13 June 2024 he still owns at least 15,999 units of uniQure N.V stock.

You can see the complete history of Leonard Post stock trades at the bottom of the page.

Leonard Post biography

DR. Leonard E. Post Ph.D. serves as Director of the Company. Since 2016, Dr. Post has served as Chief Scientific Officer of Vivace Therapeutics and its sister company, Virtuoso Therapeutics, both of which are developing oncology therapeutics. From 2010 until 2016, Dr. Post served in various positions at BioMarin (NASDAQ: BMRN), including Chief Scientific Officer, during which time he oversaw the initiation of BioMarin's first gene therapy project for hemophilia A. Prior to that, Dr. Post served as Chief Scientific Officer of LEAD Therapeutics, Senior Vice President of Research & Development at Onyx Pharmaceuticals and Vice President of Discovery Research at Parke-Davis Pharmaceuticals. He is also currently an advisor to Canaan Partners. Post is a virologist by training and did early work on engineering of herpes simplex virus as a postdoctoral fellow. He has a Bachelor of Science degree in Chemistry from the University of Michigan, and a Doctorate degree in Biochemistry from the University of Wisconsin.

How old is Leonard Post?

Leonard Post is 67, he's been the Director of uniQure N.V since 2020. There are 2 older and 13 younger executives at uniQure N.V. The oldest executive at uniQure N.V. is Jack Kaye, 76, who is the Non-Executive Independent Director.

What's Leonard Post's mailing address?

Leonard's mailing address filed with the SEC is C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.

Insiders trading at uniQure N.V

Over the last 8 years, insiders at uniQure N.V have traded over $35,572,573 worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van, Paula Soteropoulos и William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of $37,634. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth $6,309.

What does uniQure N.V do?

uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

Complete history of Leonard Post stock trades at Fulgent Genetics Inc и uniQure N.V

uniQure N.V executives and stock owners

uniQure N.V executives and other stock owners filed with the SEC include:

• Matthew Kapusta,
  Chief Executive Officer, Chief Financial Officer, Executive Director
• Robert Gut,
  Executive Director
• Alexander Kuta,
  Executive Vice President, Operations
• Maria Cantor,
  Senior Vice President, Investor Relations and Communications
• Matthew Craig Kapusta,
  CEO & Exec. Director
• Dr. Alexander E. Kuta Ph.D.,
  Exec. VP of Quality & Regulatory
• Dr. Ricardo Dolmetsch Ph.D.,
  Pres of R&D
• Christian Klemt,
  CFO, Principal Financial Officer & GM of Amsterdam Site
• David Meek,
  Non-Executive Independent Director
• Philip Astley-Sparke,
  Independent Non-Executive Chairman of the Board
• Jack Kaye,
  Non-Executive Independent Director
• Jeremy Springhorn,
  Non-Executive Independent Director
• Madhavan Balachandran,
  Non-Executive Independent Director
• Paula Soteropoulos,
  Non-Executive Independent Director
• Leonard Post,
  Director
• Ricardo Dolmetsch,
  President, Research and Development
• Erin Boyer,
  Chief People & Culture Office
• Richard Porter Ph.D.,
  SVP of R&D and GM of Corlieve
• Dr. Tamara Tugal Ph.D., MBA,
  Bus. Devel. Director
• Maria E. Cantor,
  Chief Communications Officer
• David Cerveny,
  Chief Legal Officer, Gen. Counsel & Sec.
• Pierre Caloz,
  Chief Operating Officer
• Prof. Hugo Katus,
  Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
• Rachelle Suzanne Jacques,
  Director
• Christian Meyer,
  Chief Medical Officer
• Harald Petry,
  Chief Scientific Officer
• Maiken Keson Brookes,
  General Counsel
• Jonathan Garen,
  Chief Business Officer
• David Schaffer,
  Director
• Paul E Firuta,
  Chief Commercial Officer
• William Lewis,
  Director
• Steven Zelenkofske,
  Chief Medical Officer
• Deventer Sander Van,
  EVP, Research & Product Dev.
• Scott T. Mc Millan,
  Chief Operating Officer
• Pierre Caloz,
  Chief Operating Officer
• Christian Klemt,
  Chief Financial Officer
• Jeannette Potts,
  Chief Legal Officer
• Walid Abi Saab,
  Chief Medical Officer